Celgene and Jounce in $2.6-bn Immuno-Oncology Collaboration Deal

Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.

Continue Reading

Scottish Medicines Consortium Approves Celgene’s Vidaza for MDS

The Scottish Medicines Consortium (SMC) has approved Celgene’s Vidaza (azacitidine) in patients with advanced myelodysplastic syndromes (MDS). The SMC’s decision takes into account benefits of a new patient access scheme for Vidaza, which is the only drug available in Europe for advanced myelodysplastic syndrome, a rare but debilitating disease which affects around 2,150 people in

Continue Reading